Using an orthotopic breast cancer mouse model, Hanna and colleagues [73] demonstrated that the inhibition of HH signaling with the SMOi vismodegib significantly reduced M2 macrophages, MDSCs and Treg cells in the primary tumor without affecting tumor growth, while it boosted the number of M1 macrophages, cytotoxic CD8+ T-cells and dendritic cells, decreasing pulmonary metastasis. Here, CD8A is linked to neoplasm.